Sundar S, Singh V P, Sharma S, Makharia M K, Murray H W
Kala-Azar Medical Research Center, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
J Infect Dis. 1997 Oct;176(4):1117-9. doi: 10.1086/516526.
One hundred fifty-six previously untreated Indian patients with visceral leishmaniasis were treated with pentavalent antimony (Sb) alone for 30 days (group A), Sb plus interferon-gamma (IFN-gamma) for 30 days (group B), or Sb plus IFN-gamma for 15 days (group C). The purpose was to show that IFN-gamma would increase the response to 30 days of Sb treatment and that short-course (15 days) combination therapy was as effective as 30 days of Sb alone. Six months after treatment, 36% of group A, 49% of group B, and 42% of group C patients were designated as definitively cured. The success rates for long-term responses to Sb alone (36%) and Sb plus IFN-gamma (49%) were unexpectedly low, and responses in groups A, B, and C were not significantly different. These results suggest that the beneficial effects of adjunctive IFN-gamma in visceral leishmaniasis may be limited in regions where this disseminated intracellular infection shows high-level resistance to Sb.
156名先前未经治疗的印度内脏利什曼病患者分别接受以下治疗：仅用五价锑（Sb）治疗30天（A组）；Sb加干扰素-γ（IFN-γ）治疗30天（B组）；或Sb加IFN-γ治疗15天（C组）。目的是证明IFN-γ会增强对30天Sb治疗的反应，并且短疗程（15天）联合治疗与仅用30天Sb治疗的效果相同。治疗6个月后，A组36%、B组49%和C组42%的患者被确定为完全治愈。仅用Sb（36%）和Sb加IFN-γ（49%）的长期反应成功率出乎意料地低，且A、B、C三组的反应无显著差异。这些结果表明，在这种播散性细胞内感染对Sb表现出高度耐药性的地区，辅助性IFN-γ在内脏利什曼病中的有益作用可能有限。
